- Email: [email protected]
Pall opens centre of excellence in India
of our employees in Waynesboro and throughout the Small Engine and Recreational Vehicle (SERV) business, who have worked hard to turn this business around. Given the continued losses in this segment and little prospect for improvement, however, this is the right decision for the future success of Cummins Filtration.” The Waynesboro facility, which opened in 2003, produces exhaust systems and structural frame components for small engine applications such as lawn and garden equipment and all-terrain vehicles. It is the only Cummins Filtration facility devoted solely to SERV products. The segment has remained unprofitable for the past three years, despite a significant investment of people and resources into the business. All current supply agreements will be honoured and the company will work with customers to help with the transition to new suppliers. Cummins Filtration also is committed to maintaining its facility in Waynesboro as it actively pursues a buyer.
PALL OPENS CENTRE OF EXCELLENCE IN INDIA Pall Corp has inaugurated its newest Life Sciences Centre of Excellence in Bangalore, India. The centre will drive process optimization innovations for the global life sciences market to meet the evolving opportunities and challenges of this fast-growing industry throughout Asia. The new centre includes a state-of-the-art proteomics laboratory to help customers speed the drug discovery process. It also houses a validation laboratory and a training facility with specialty experts to support Indian and regional customers as they
Filtration Industry Analyst
increasingly enter the stringently regulated drug export market. India was strategically chosen as the location for Pall’s new Centre of Excellence in Asia because of the country’s highly regarded reputation in life sciences spanning biopharmaceutical research, development and production. Additionally, Pall says that India’s diverse market opportunities coupled with a large pool of qualified scientists and engineers provide an ideal climate for fuelling innovation and growth. “Pall’s growth in the Asian life sciences market is a reflection of our focus on this important region and our continuing commitment to undertake several customer-centric initiatives there,” says Roberto Perez, president, Pall Life Sciences Worldwide. “The new Centre of Excellence will be instrumental in helping the life sciences industry in India and throughout the region apply the latest technologies and services to their operations, so they have the optimal tools and expertise to bring new and innovative drugs to market more efficiently.” The new centre will provide the pharmaceutical, biotechnology and discovery markets throughout the region with a full range of total fluid management solutions. Led by a team of professionals, the new centre joins other Pall Life Sciences Centres of Excellence throughout Europe and the Western Hemisphere in bringing together the latest technologies with process optimization knowledge and expertise. “The success of our customers depends on their ability to carry out all stages of drug development- research, discovery and full-scale production - efficiently and costeffectively,” said Vinay Joban, general manager, Pall BioPharmaceuticals India. “The new centre provides the region
with a complete range of services to support their operations from upstream through downstream while also facilitating their ability to comply with increasingly rigorous global requirements.” “Our new Centre of Excellence is the latest demonstration of Pall’s long-term commitment to grow and invest in Asia and align with our customer’s worldwide,” says Vinay Gupta, managing director and head of Pall Life Sciences in India. “It is key to our global strategy of working as a partner with the pharmaceutical and biotechnology industries and the academic research community to provide them with a full range of total process management solutions for improved optimization.” Pall has been present in India for more than two decades and was incorporated as Pall India in 1996. Headquartered in Mumbai, the company serves both Life Sciences and Industrial markets where it provides total fluid management solutions for a broad range of critical applications to a diverse customer base. With more than 200 employees drawn from various disciplines and expertise, Pall continues to enhance and expand its operations in India. Currently, plans are underway to set up a new centre in Pune to provide complete engineering solutions to the global market for Pall’s housings and systems portfolio. In addition to its operations in India, Pall serves the AsiaPacific region with facilities in China, Indonesia, Japan, Korea, Malaysia, Australia, New Zealand, Philippines, Singapore, Taiwan, Thailand and Vietnam.
CLARCOR COMPLETES US$50 MN SHARE BUYBACK Clarcor Inc purchased 1 550 000 shares of its common
stock on the open market during the month of April at an average price of US$31.83 per share. These purchases were made under the company’s previously announced share repurchase authorization. Approximately US$60 million remains available to effect additional purchases under the current authorization, which expires in June 2007. “The management and board of directors of Clarcor believe that the purchase of the company’s stock at the price levels recently available in the market represented a great investment for our company and our shareholders. We have ample cash flow and borrowing capacity to pursue a variety of strategic initiatives and investments, including acquisitions and additional share repurchases,” explained Norm Johnson, Clarcor’s chairman and chief executive officer (CEO).
MICROFILTREX EXTENDS WITH LAB RANGE To support demand from the Life Sciences’ industry, Porvair’s Microfiltrex has extended its filtration and separation capability with the addition of small-scale filtration products. Positioned to provide solutions to laboratory bioprocessing applications including clarification, sterile filtration, venting and gas filtration, the Lab Range comprises syringe filters and devices, a selection of filter capsules and junior cartridge filters, with a choice of media, pore size and connections. “Following success with our Microfiltration product range for Life Sciences, we identified a customer need for small-scale filtration products, a niche that the Lab Range fulfils,” says Bob Wilkinson, general manager, Microfiltration.
3
NEWS
May 2007
PALL OPENS CENTRE OF EXCELLENCE IN INDIA Pall Corp has inaugurated its newest Life Sciences Centre of Excellence in Bangalore, India. The centre will drive process optimization innovations for the global life sciences market to meet the evolving opportunities and challenges of this fast-growing industry throughout Asia. The new centre includes a state-of-the-art proteomics laboratory to help customers speed the drug discovery process. It also houses a validation laboratory and a training facility with specialty experts to support Indian and regional customers as they
Filtration Industry Analyst
increasingly enter the stringently regulated drug export market. India was strategically chosen as the location for Pall’s new Centre of Excellence in Asia because of the country’s highly regarded reputation in life sciences spanning biopharmaceutical research, development and production. Additionally, Pall says that India’s diverse market opportunities coupled with a large pool of qualified scientists and engineers provide an ideal climate for fuelling innovation and growth. “Pall’s growth in the Asian life sciences market is a reflection of our focus on this important region and our continuing commitment to undertake several customer-centric initiatives there,” says Roberto Perez, president, Pall Life Sciences Worldwide. “The new Centre of Excellence will be instrumental in helping the life sciences industry in India and throughout the region apply the latest technologies and services to their operations, so they have the optimal tools and expertise to bring new and innovative drugs to market more efficiently.” The new centre will provide the pharmaceutical, biotechnology and discovery markets throughout the region with a full range of total fluid management solutions. Led by a team of professionals, the new centre joins other Pall Life Sciences Centres of Excellence throughout Europe and the Western Hemisphere in bringing together the latest technologies with process optimization knowledge and expertise. “The success of our customers depends on their ability to carry out all stages of drug development- research, discovery and full-scale production - efficiently and costeffectively,” said Vinay Joban, general manager, Pall BioPharmaceuticals India. “The new centre provides the region
with a complete range of services to support their operations from upstream through downstream while also facilitating their ability to comply with increasingly rigorous global requirements.” “Our new Centre of Excellence is the latest demonstration of Pall’s long-term commitment to grow and invest in Asia and align with our customer’s worldwide,” says Vinay Gupta, managing director and head of Pall Life Sciences in India. “It is key to our global strategy of working as a partner with the pharmaceutical and biotechnology industries and the academic research community to provide them with a full range of total process management solutions for improved optimization.” Pall has been present in India for more than two decades and was incorporated as Pall India in 1996. Headquartered in Mumbai, the company serves both Life Sciences and Industrial markets where it provides total fluid management solutions for a broad range of critical applications to a diverse customer base. With more than 200 employees drawn from various disciplines and expertise, Pall continues to enhance and expand its operations in India. Currently, plans are underway to set up a new centre in Pune to provide complete engineering solutions to the global market for Pall’s housings and systems portfolio. In addition to its operations in India, Pall serves the AsiaPacific region with facilities in China, Indonesia, Japan, Korea, Malaysia, Australia, New Zealand, Philippines, Singapore, Taiwan, Thailand and Vietnam.
CLARCOR COMPLETES US$50 MN SHARE BUYBACK Clarcor Inc purchased 1 550 000 shares of its common
stock on the open market during the month of April at an average price of US$31.83 per share. These purchases were made under the company’s previously announced share repurchase authorization. Approximately US$60 million remains available to effect additional purchases under the current authorization, which expires in June 2007. “The management and board of directors of Clarcor believe that the purchase of the company’s stock at the price levels recently available in the market represented a great investment for our company and our shareholders. We have ample cash flow and borrowing capacity to pursue a variety of strategic initiatives and investments, including acquisitions and additional share repurchases,” explained Norm Johnson, Clarcor’s chairman and chief executive officer (CEO).
MICROFILTREX EXTENDS WITH LAB RANGE To support demand from the Life Sciences’ industry, Porvair’s Microfiltrex has extended its filtration and separation capability with the addition of small-scale filtration products. Positioned to provide solutions to laboratory bioprocessing applications including clarification, sterile filtration, venting and gas filtration, the Lab Range comprises syringe filters and devices, a selection of filter capsules and junior cartridge filters, with a choice of media, pore size and connections. “Following success with our Microfiltration product range for Life Sciences, we identified a customer need for small-scale filtration products, a niche that the Lab Range fulfils,” says Bob Wilkinson, general manager, Microfiltration.
3
NEWS
May 2007